Replies to post #12213 on ANI Pharmaceuticals (ANIP)

[LordDarley]

Catty, Jake, and anyone else.

Get the hell out of this. You can always buy back. The 10-Q and the conference call made clear there was no silver bullet.

I'm no investment advisor, and have demonstrated stupidity in the past by buying this dog at prices as high as $80.

There are just times when you need to folow the advice of the great Kenny Rogers. Know when to fold them.

Enough. I'm going back to the investments I have now. The only thing that brings me back here is fondness for a few of you.

[Just the facts maam]

Catty, rightly, or wrong, I got in early on the Libigel discoveries. I believed for several reasons that it was being set up as a revenue replacement for when AbbVie's Humira faced biosimilar competition originally though to be 2019 in the US but with successful patent litigation and signed deals AbbVie was able to delay the biosimilar launches in the US until 2023. There is still a chance that this may happen and I am willing to wait it out. For me as an early investor the reward is worth the risk. For those underwater obviously it is a much harder decision. This is why I am holding until 2023.